Home >> News >> Business >> Antinuclear Antibody Testing Market Is Expected To Reach US$ 1,588.7 Bn By 2025

Antinuclear Antibody Testing Market Is Expected To Reach US$ 1,588.7 Bn By 2025

According to the latest market report published by Credence Research, Inc. “Antinuclear Antibody Tests Market – Growth, Future Prospects, and Competitive Analysis, 2017 – 2025,” the global antinuclear antibody tests market was valued at US$ 649 Mn in 2016, and is expected to reach US$ 1,588.7 Mn by 2025, expanding at a CAGR of 9.8% from 2017 to 2025

The purpose of the report is to illustrate the state of the market of Antinuclear Antibody Testing, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.

Browse here for full report: https://www.credenceresearch.com/report/anti-nuclear-antibody-testing-ana-market

Market Insights

An antinuclear antibody tests (ANA) are used to evaluate quantity and pattern of antibodies in the blood. It is used to evaluate autoimmune disorders that might affect tissues and organ throughout systemic body. It is commonly used to diagnose rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjögren syndrome, scleroderma and polymyositis. Usually any foreign body such as virus or bacteria if enters the body, would be destroyed by the immune system. In autoimmune disorder, body produces ANA as group of antibodies, as the immune system is not able to differentiate between “self” and “nonself.” It targets the nucleus of the cell and destroys the tissue and the organ. Rising prevalence of autoimmune disorders, advancement in lab automation and use of novel biomarker are the key factors driving the growth of antinuclear antibody tests market

The global antinuclear antibody tests market is segmented by product type into reagent & assays kits, systems and software & services. Reagents and assay kits occupy the largest share of global antinuclear antibody tests market. The global antinuclear antibody tests market is segmented by technique type into enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay and multiplex assay. Enzyme-Linked Immunosorbent Assay (ELISA) dominates the global antinuclear antibody tests market. By disease, global antinuclear antibody tests market is segmented into rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, scleroderma and other diseases. Rheumatoid arthritis currently occupies the largest market share of global antibody tests market due to rising prevalence of rheumatoid arthritis.

As of the current market scenario, North America dominated the global antinuclear antibody tests market followed by the Europe. Factors contributing to the growth of North America market includes increase in prevalence of autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), growing introduction and availability of novel diagnostic tools and supportive reimbursement policies. Asia Pacific is the fastest growing regional market for antinuclear antibody tests.

Market Competition Assessment:

Key players in the global antinuclear antibody test market are Alere, Inc., EUROIMMUN AG, ERBA Diagnostics, Inc., Trinity Biotech plc, Bio-Rad Laboratories, Inc., Immuno Concepts, Thermo Fisher Scientific, Inc., Antibodies, Inc., Inova Diagnostics, Zeus Scientific, Inc. and others.

Why was the report written?

This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Antinuclear Antibody Testing buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.

What is the current market landscape and what is changing?

Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.

The report on the market of Antinuclear Antibody Testing contains:

Analysis and forecast of Antinuclear Antibody Testing market dynamics;

Analysis of domestic production, market shares of the main market players;

Analysis of exports and imports;

Analysis of factors, leading the development of the Antinuclear Antibody Testing market;

Assessment and forecast of Antinuclear Antibody Testing market development;

Financial and business profiles of the leading companies in the Antinuclear Antibody Testing industry.


– Up to date working Antinuclear Antibody Testing data by major regions in the world, the forecast of planned capacity additions by 2026

– The annual breakdown of capital expenditure spending on proposed Antinuclear Antibody Testing for the period 2018 to 2026

– Planned Antinuclear Antibody Testing additions and capital expenditure spending by key countries and companies across the world

– Planned capital expenditure spending on new Antinuclear Antibody Testing projects by region, key countries, and companies

– Details of major planned Antinuclear Antibody Testing projects in the world up to 2026

Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/58594

About Us

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Contact Us:

Credence Research Inc.

105 N 1st ST #429


CA 95103

United States

Toll Free (US/CANADA): +1-800-361-8290

Web: https://www.credenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *